- Home
- Services
- usa new jersey
- therapeutic neutralizing antibodies
Therapeutic Neutralizing Antibodies Services In Usa New Jersey
5 services found
by:Biointron based inShanghai, CHINA
As a result of the advances in antibody discovery technologies in hybridoma, display libraries, Single B-cell sorting/sequencing and computational modeling, thousands of mAbs have been generated in antibody discovery campaigns. To rapidly find “best-in-class” antibody therapeutics, it has become essential to develop high throughput (HTP) processes that allow rapid assessment of ...
by:Biointron based inShanghai, CHINA
Nanobody (sdAb or VHH) is a promising next-generation therapeutic antibody technology for cancer immunotherapy and other applications. Nanobodies are distinguished from other conventional antibody formats by their unique properties of size, solubility, intrinsic stability, easy tailoring into pluripotent constructs, recognition of uncommon or hidden epitopes, binding into cavities or active sites ...
Manufactured by:Synbio Technologies LLC based in, NEW JERSEY (USA)
Immunogenicity or Human Anti-Mouse Antibodies (HAMA) response is what happens when antibodies derived from xenogeneic sources are administered to humans. This can potentially decrease the effectiveness of immune-treatment through rapid clearance of the therapeutic antibody or immune-conjugate. In some cases, the patient may even develop an allergic sensitivity and be at risk of anaphylactic shock ...
Manufactured by:Beta Lifescience based inPaoli, NEW JERSEY (USA)
Beta Lifesciences has accumulated an extensive experience in the development of recombinant proteins. We have rich experience in the expression of recombinant proteins (antibodies, enzymes, membrane proteins, cytokines, etc.) in any species. We provide recombinant protein expression and purification services from small-scale to large-scale. According to the customer's needs, our scientists will ...
Manufactured by:Synbio Technologies LLC based in, NEW JERSEY (USA)
In recent years, the proportion of biological drugs in the global pharmaceutical market has been close to 20%. The focus within the global pharmaceutical market has been gradually shifting from small molecule chemical drugs to biomacromolecules (biological drugs). It also appears that the trend is gradually expanding. Biological drugs are a broad class of pharmaceuticals generated by using ...